Skip to main content
. Author manuscript; available in PMC: 2016 Nov 8.
Published in final edited form as: J Clin Endocrinol Metab. 2009 Jun 30;94(9):3215–3225. doi: 10.1210/jc.2008-2765

FIG. 1.

FIG. 1

Effect of baseline risk factors on reduction in vertebral fracture with zoledronic acid 5 mg at 3 yr in stratum I. OP, Osteoporosis (femoral neck T-score ≤−2.5); VFx, vertebral fracture; BP, bisphosphonate; CrCl, creatinine clearance; ZOL, zoledronic acid; CI, confidence interval. *, Vertebral fracture risk was assessed in the stratum I modified intent-to-treat population.

HHS Vulnerability Disclosure